EVAX Evaxion
NEUTRAL
Impact: 2/10
PRESS-RELEASE
Press release: announcement
Latest settled — T+20d ⚠ clustered
EVAX ▲ +0.48% at T+20d
NEUTRAL call ✓ call won +0.48% · α vs SPY -5.33% · entry $4.14 → $4.16
Currently $3.64 · -12.08% from $4.14 entry
T+1d
+7.49%
call +7.49% · α +6.27%
$4.45
settled 8w ago
T+5d
+2.66%
call +2.66% · α +1.67%
$4.25
settled 7w ago
T+20d
+0.48%
call +0.48% · α -5.33%
$4.16
settled 4w ago
T+60d
—
call — · α —
—
in 4w
Price Chart
Loading chart...
Executive Summary
Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board members while adding one new director. The filing is a routine corporate governance update with no material financial or strategic developments disclosed.
Actionable Insight
No immediate trading implications. Monitor upcoming clinical trial updates or financing announcements, which would be more material catalysts for this micro-cap biotech.
Key Facts
- Annual General Meeting held on April 16, 2026
- 2025 Annual Report approved
- Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda re-elected to Board
- Jens Bitsch Nørhave newly elected to Board
- No changes to executive leadership or company strategy announced
Financial Impact
No financial impact
Risk Factors
- Forward-looking statements highlight risks related to funding needs and clinical development
- Small market cap ($35M) increases volatility and sensitivity to future dilution
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275638 |
23 reports for EVAX
100%
Hit rate
best @ T+5▲ +22.94%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
6-K
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 12, 2026
1d ago
|
Press Release
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 11, 2026
2d ago
|
6-K
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
Jun 11, 2026
2d ago
|
Press Release
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
May 12, 2026
4w ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 7, 2026
5w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.64 (−10.57%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.64 (−20.35%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
Showing 10 of 23
US Market Status
Market Closed — Opens Mon (47h 21m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access